Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
David Bickers MD

David R. Bickers MD

Carl Truman Nelson Professor and Chair, Department of Dermatology, Columbia University Irving Medical Center, New York, New York

David R. Bickers, MD, is the Carl Truman Nelson Professor and Chair of Dermatology at Columbia University Irving Medical Center in New York. He is a physician-scientist investigating the carcinogenic effects of skin exposure to solar ultraviolet radiation. This has led to research directed at identifying mechanism-driven strategies for managing patients with basal cell carcinomas (BCCs). Dr. Bickers has been actively involved in clinical trials employing targeted agents in a cohort of patients with Basal Cell Nevus Syndrome (BCNS) or Gorlin syndrome, a dominantly inherited disorder associated with mutations in the Sonic hedgehog signaling pathway (Shh). These studies have verified the efficacy of targeting Shh signaling in abrogating the growth of BCCs and their considerable tumor burden in BCNS patients. These studies and others led to the FDA approval of the Smoothened inhibitor, vismodegib, for the treatment of advanced surgically inoperable BCCs. Unfortunately, the clinical utility of currently available Shh inhibitors is hampered by the development of tumor resistance and substantial tumor regrowth, underscoring the belief that Shh signaling inhibition alone is insufficient for permanent eradication of BCCs. Dr. Bickers' laboratory is seeking to develop novel combinatorial treatment strategies to ultimately prevent/reduce the tumor burden in BCNS patients.


Dr. Bickers has no relevant disclosures.